<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metyrapone stimulation tests</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metyrapone stimulation tests</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Metyrapone stimulation tests</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hershel Raff, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> stimulation test is based upon the principle that it inhibits conversion of 11-deoxycortisol to cortisol. The resultant decrease in serum cortisol concentrations should be followed by an increase in corticotropin (ACTH) secretion and the immediate precursor of cortisol, 11-deoxycortisol [<a href="#rid1">1</a>]. An inability of the hypothalamic-pituitary-adrenal (HPA) axis to respond appropriately to the decreased glucocorticoid feedback is shown by lower-than-normal increases in 11-deoxycortisiol. Compared with the insulin-induced hypoglycemia test, the metyrapone stimulation test has been considered to be more physiological, with fewer adverse side effects.</p><p>During the last 10 years, the availability of <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> and measurements of 11-deoxycortisol in blood and urine decreased or stopped in many countries. At the same time, synthetic ACTH and cortisol assays were widely available [<a href="#rid2">2,3</a>]. As a result, the <a class="drug drug_general" data-topicid="9298" href="/z/d/drug information/9298.html" rel="external">ACTH stimulation test</a> often was used instead of metyrapone.</p><p>However, with enhanced availability of <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> and more specific techniques to measure serum 11-deoxycortisol, the test may be performed more frequently [<a href="#rid2">2,3</a>]. This topic will focus on the physiological mechanisms that underlie its usefulness as an alternative test to evaluate ACTH secretory reserve, particularly when the insulin-induced hypoglycemia test may be contraindicated or inconvenient [<a href="#rid4">4-6</a>]. Other tests to evaluate the HPA axis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults"</a> and  <a class="medical medical_review" href="/z/d/html/164.html" rel="external">"Insulin-induced hypoglycemia test protocol"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>As described above, the <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> stimulation test is based upon the principle that decreasing serum cortisol concentrations normally cause an increase in corticotropin-releasing hormone (CRH) secretion from the hypothalamus and corticotropin (ACTH) secretion from the anterior pituitary due to a decrease in glucocorticoid negative feedback. The test is performed primarily to detect partial defects in pituitary ACTH secretion.</p><p>11-deoxycortisol, the substrate for CYP11B1, increases due to <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> inhibition of the enzyme. Because it is essentially devoid of glucocorticoid activity, it does not inhibit ACTH secretion. Thus, in healthy individuals, the decreased negative feedback after metyrapone increases CRH and ACTH secretion and adrenal steroidogenesis. However, due to the block of CYP11B1, only cortisol precursors are secreted. In particular, serum 11-deoxycortisol concentrations can be measured by immunoassay, high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), or fast liquid chromatography-tandem mass spectrometry (LC-MS/MS). Alternatively, its urinary metabolites may be measured [<a href="#rid7">7</a>].</p><p>The increase in serum 11-deoxycortisol concentration provides an index of the increase in ACTH release; a lack of increase can indicate either ACTH deficiency or primary adrenal disease. Thus, if the <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> test is abnormal, additional tests are needed to distinguish between these disorders. (See  <a class="medical medical_review" href="/z/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PROCEDURE</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> test is performed as an overnight, single-dose test based on blood levels of 11-deoxycortisol. It should not be used in a patient who is taking supraphysiologic doses of glucocorticoid. Metyrapone is currently available through its distributor HRA Pharma (Paris, France) in many countries worldwide. In the United States, it can be obtained via its specialty pharmacy (https://metopirone.com/home-hcp/accessing-metopirone [phone 1-800-320-2112]).</p><p><a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">Metyrapone</a> administration may result in hypotension, nausea, and vomiting in patients with adrenal insufficiency; as a result, it should not be utilized in patients suspected of having severe adrenal insufficiency. (See <a class="local">'Metyrapone side effects'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h2">Overnight, single-dose metyrapone test</span><span class="headingEndMark"> — </span>This test is safe for outpatient use [<a href="#rid4">4-6,8-10</a>]. <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">Metyrapone</a> is taken orally (30 mg/kg body weight, or 2 grams for &lt;70 kg, 2.5 grams for 70 to 90 kg, and 3 grams for &gt;90 kg body weight) at midnight with a glass of milk or a small snack [<a href="#rid11">11</a>]. Serum 11-deoxycortisol and cortisol are measured between 7:30 and 9:30 AM the next morning; plasma corticotropin (ACTH) can also be measured [<a href="#rid1">1,4,8-12</a>]. </p><p>Some cortisol immunoassays have significant cross-reactivity with 11-deoxycortisol and may lead to a spuriously high cortisol result. To avoid this problem, specific cortisol immunoassays or tandem mass spectrometry (which does not cross-react with 11-deoxycortisol) should be used [<a href="#rid13">13</a>]. Note that these specific serum 11-deoxycortisol assays are typically only available in reference laboratories, and it can take up to a week to get the results. Other dosing regimens have been used [<a href="#rid2">2</a>].</p><p>A normal response to the overnight, single-dose test consists of:</p><p class="bulletIndent1"><span class="glyph">●</span>A morning (7:30 to 9:30 AM) serum 11-deoxycortisol concentration of 7 to 22 mcg/dL (200 to 635 nmol/L) [<a href="#rid4">4,6,8,11,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A simultaneous serum cortisol concentration of less than 5 mcg/dL (138 nmol/L); this confirms adequate <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> blockade and thereby documents compliance and normal metabolism of metyrapone.</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Metyrapone side effects</span><span class="headingEndMark"> — </span>By reducing cortisol production more dramatically in patients with adrenal insufficiency than in healthy people, <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> can result in symptoms of adrenal insufficiency, such as hypotension, nausea, vomiting, abdominal discomfort or cramping, and muscle and joint pain in these patients. Metyrapone also can cause dizziness, sedation, allergic rash, or, rarely, decreased white blood cell count or bone marrow suppression. In one study, <a class="drug drug_general" data-topicid="8535" href="/z/d/drug information/8535.html" rel="external">hydrocortisone</a> 10 mg was administered once samples were collected, before discharging the patient [<a href="#rid2">2</a>]. This may be helpful in patients in whom severe adrenal insufficiency is suspected, or in patients with adverse reactions suggestive of adrenal insufficiency. However, studies that have not used this approach do not report a higher incidence of adverse outcomes.</p><p class="headingAnchor" id="H8"><span class="h1">INTERPRETATION</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> test is a sensitive test of pituitary corticotropin (ACTH) secretory reserve; it was more sensitive than insulin tolerance test in certain studies [<a href="#rid6">6</a>] or slightly less in other studies [<a href="#rid15">15</a>]. This difference depends upon the degree of pituitary ACTH increase in response to negative feedback inhibition by cortisol; hypocortisolemia is a less potent stimulus of ACTH release than hypoglycemia or other stresses. Thus, a patient with partial hypopituitarism may maintain normal daily ACTH and cortisol secretion and respond to insulin-induced hypoglycemia with an appropriate increase in ACTH and cortisol secretion, yet be unable to increase ACTH secretion appropriately when cortisol biosynthesis is blocked by metyrapone [<a href="#rid8">8</a>]. Conversely, a patient who responds normally to metyrapone almost always responds normally to hypoglycemia or other stresses.</p><p class="headingAnchor" id="H77033422"><span class="h2">Normal response</span><span class="headingEndMark"> — </span>When used to diagnose hypoadrenalism, a normal response to the <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> tests indicates an intact hypothalamic-pituitary-adrenal (HPA) axis; such a patient does not have any form of adrenal insufficiency and requires no further investigation. An abnormal test could reflect either primary or secondary adrenal insufficiency. Distinction between the two can be determined by finding a high basal or metyrapone-stimulated plasma ACTH concentration, which would indicate primary adrenal insufficiency [<a href="#rid4">4,5,16</a>].</p><p class="headingAnchor" id="H2451347996"><span class="h2">Partial defects in ACTH secretion</span><span class="headingEndMark"> — </span>The <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> test is a sensitive method to detect partial defects in pituitary corticotropin (ACTH) secretion [<a href="#rid4">4-6,17</a>]. Thus, morning basal plasma ACTH and serum cortisol concentrations, basal urinary excretion of cortisol, and the responses to insulin-induced hypoglycemia and both the 1 and 250 mcg ACTH stimulation tests may all be normal, but the metyrapone test may be subnormal [<a href="#rid10">10,18</a>]. An example would be a patient with a suspected pituitary mass who has no clinical manifestations of ACTH deficiency, an intermediate 8 AM serum cortisol concentration, but an abnormal metyrapone test. (See  <a class="medical medical_review" href="/z/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a> and  <a class="medical medical_review" href="/z/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults"</a>.)</p><p>Serum 11-deoxycortisol concentrations less than 7 mcg/dL (202 nmol/L) with concomitantly suppressed cortisol values indicate adrenal insufficiency.</p><p class="bulletIndent1">However, in one study, the sum of 11-deoxycortisol and of cortisol &gt;15 mcg/dL (450 nmol/L) following a single-dose, overnight <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> test yielded better diagnostic accuracy than using 11-deoxycortisol levels alone [<a href="#rid5">5</a>]. In a study of 31 patients with various HPA axis abnormalities comparing insulin tolerance test with overnight metyrapone test, a cutoff of 144 nmol/L (5 mcg/dL) for 11-deoxycortisol yielded the highest sensitivity of 82.4 percent to detect patients responding normally to insulin tolerance test, but only 64.3 percent of those with subnormal response to insulin tolerance test [<a href="#rid15">15</a>].</p><p></p><p>In the evaluation of mild secondary adrenal insufficiency after pituitary surgery, it is best to wait for six weeks to perform the overnight <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> test. In one study, 37 percent of patients with an abnormal test on day 6 after metyrapone subsequently had a normal response [<a href="#rid19">19</a>].</p><p>In a study examining potential secondary adrenal insufficiency in 40 opioid users with non-cancer pain, 22 percent were found to have adrenal insufficiency using 250 mcg ACTH 1-24 test and the overnight <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> test, but the tests were concordant in only half. The small number of patients and the lack of comparison with insulin-induced hypoglycemia limit the ability to determine which test is superior [<a href="#rid20">20</a>].</p><p>In 21 subjects with Prader-Willi syndrome evaluated for possible central adrenal insufficiency, six (29 percent) had peak cortisol &lt;15.5 mcg/dL (428 nmol/L) after injection of 1 mcg ACTH 1-24, but normal overnight <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> 11-deoxycortisol results in 20 of 21 subjects. The lack of clinical symptoms of adrenal insufficiency suggested that the overnight metyrapone test was more reliable in this condition [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3541141777"><span class="h2">Primary versus secondary adrenal insufficiency</span><span class="headingEndMark"> — </span>Theoretically, the ACTH response to <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> may distinguish between primary and secondary insufficiency, but it is neither used nor recommended for this purpose. In general, patients with partial secondary adrenal insufficiency have ACTH responses from 10 to 200 pg/mL (2 to 44 pmol/L), while patients with primary adrenal insufficiency have higher responses [<a href="#rid4">4,5,16</a>]. However, healthy individuals have an ACTH response of 42 to 690 pg/mL (9 to 210 pmol/L) [<a href="#rid22">22</a>]. Because of this overlap, the ACTH response alone cannot be used to distinguish between healthy individuals and those with adrenal insufficiency. As noted, the modern, high-sensitivity immunometric ACTH assay has rendered the metyrapone test unnecessary in most patients for differentiating primary and secondary adrenal insufficiency. (See  <a class="medical medical_review" href="/z/d/html/154.html" rel="external">"Determining the etiology of adrenal insufficiency in adults", section on 'Establish the level of defect'</a>.)</p><p></p><p class="headingAnchor" id="H1139068104"><span class="h2">False-negative results</span><span class="headingEndMark"> — </span>The increase in serum 11-deoxycortisol concentrations may be exaggerated in some individuals, including those with hypothyroidism, hypoglycemia, diabetes mellitus, congestive heart failure, obesity, and chronic renal failure [<a href="#rid23">23,24</a>]. As a result, findings in such individuals may falsely be considered normal.</p><p class="headingAnchor" id="H10"><span class="h2">False-positive results</span><span class="headingEndMark"> — </span>There are settings in which false-positive results can be obtained:</p><p class="bulletIndent1"><span class="glyph">●</span>Unappreciated recent exposure to supraphysiologic doses of synthetic glucocorticoids by any route can result in a subnormal response as a result of suppression of the corticotropes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One of the more common causes of a false-positive result is unusually rapid clearance of <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> from the plasma, which occurs in approximately 4 percent of healthy individuals [<a href="#rid23">23,25</a>]. This results in inadequate blockade of cortisol biosynthesis and an 8 AM serum cortisol concentration of greater than 7.5 mcg/dL (210 nmol/L). Metyrapone is metabolized by hepatic cytochrome P450 enzymes that are induced by many of the same drugs that increase steroid metabolism (eg, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9659" href="/z/d/drug information/9659.html" rel="external">mitotane</a>). Therefore, these drugs should be stopped well before the metyrapone test is performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cortisol levels measured by conventional immunoassays can theoretically be falsely elevated by the interference of increased 11-deoxycortisol levels induced by <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a>. Since the cross-reactivity of 11-deoxycortisol in the typical cortisol immunoassay is &lt;5 percent and often &lt;2 percent [<a href="#rid2">2</a>], this is usually a minor issue in most patients. Furthermore, the wider availability of liquid chromatography-tandem mass spectrometry (LC-MS/MS) steroid assays eliminates this concern [<a href="#rid26">26</a>]. However, obtaining a serum cortisol concentration by LC-MS/MS may require a special request to the local clinical laboratory; most laboratories routinely use a platform immunoassay.</p><p></p><p class="headingAnchor" id="H3936688566"><span class="h2">Postoperative assessment of patients with Cushing disease</span><span class="headingEndMark"> — </span>Recurrence of Cushing disease after pituitary surgery is common, and early identification of relapse is important [<a href="#rid27">27</a>]. It has been suggested that an increase in 11-deoxycortisol to greater than 5.2 mcg/dL (150 nmol/L) with a <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> test administered 14 days after pituitary surgery is predictive of relapse [<a href="#rid28">28</a>]. However, other approaches are likely to be more useful. (See  <a class="medical medical_review" href="/z/d/html/118.html" rel="external">"Primary therapy of Cushing disease: Transsphenoidal surgery and pituitary irradiation", section on 'Biochemical criteria'</a>.)</p><p class="headingAnchor" id="H1773050266"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112295.html" rel="external">"Society guideline links: Adrenal insufficiency"</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles of test </strong>–<strong> </strong><a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">Metyrapone</a> blocks the conversion of 11-deoxycortisol to cortisol by CYP11B1 (11-beta-hydroxylase, P450c11), the last step in the synthesis of cortisol, and induces a rapid fall of cortisol  (<a class="graphic graphic_figure graphicRef56413" href="/z/d/graphic/56413.html" rel="external">figure 1</a>). (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1">The <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> stimulation test is based upon the principle that decreasing serum cortisol concentrations normally produce an increase in corticotropin-releasing hormone (CRH) and corticotropin (ACTH) secretion due to a decrease in glucocorticoid negative feedback. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for test </strong>–<strong> </strong>The test is performed primarily to detect partial defects in pituitary ACTH secretion and may be more physiological and less dangerous than insulin-induced hypoglycemia. In many countries, the <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">metyrapone</a> stimulation test has been used infrequently during the last 10 years, but this may change with the improved availability of metyrapone and a more specific measurement of serum 11-deoxycortisol performed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal response </strong>–<strong> </strong>In healthy individuals, the decrease in serum cortisol concentrations leads sequentially to increases in ACTH secretion, adrenal steroidogenesis, and the secretion of cortisol precursors; in particular, 11-deoxycortisol, which can be measured by immunoassay, high-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), or LC-MS/MS. (See <a class="local">'Interpretation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation </strong>–<strong> </strong>The increase in serum 11-deoxycortisol concentrations provides an index of the increase in ACTH release; a lack of increase in 11-deoxycortisol can indicate either ACTH deficiency or primary adrenal disease. Distinction between the two can be determined by finding a high basal or stimulated plasma ACTH concentration, which would indicate primary adrenal insufficiency. (See <a class="local">'Primary versus secondary adrenal insufficiency'</a> above.)</p><p></p><p class="headingAnchor" id="H2959669655"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Raff H, Findling JW, Wong J. Short loop adrenocorticotropin (ACTH) feedback after ACTH-(1-24) injection in man is an artifact of the immunoradiometric assay. J Clin Endocrinol Metab 1989; 69:678.</a></li><li><a class="nounderline abstract_t">Cegla J, Jones B, Seyani L, et al. Comparison of the overnight metyrapone and glucagon stimulation tests in the assessment of secondary hypoadrenalism. Clin Endocrinol (Oxf) 2013; 78:738.</a></li><li><a class="nounderline abstract_t">van Aken MO, de Herder WW, van der Lely AJ, et al. Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease. Clin Endocrinol (Oxf) 1997; 47:145.</a></li><li><a class="nounderline abstract_t">Fiad TM, Kirby JM, Cunningham SK, McKenna TJ. The overnight single-dose metyrapone test is a simple and reliable index of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf) 1994; 40:603.</a></li><li><a class="nounderline abstract_t">Berneis K, Staub JJ, Gessler A, et al. Combined stimulation of adrenocorticotropin and compound-S by single dose metyrapone test as an outpatient procedure to assess hypothalamic-pituitary-adrenal function. J Clin Endocrinol Metab 2002; 87:5470.</a></li><li><a class="nounderline abstract_t">Gibney J, Healy ML, Smith TP, McKenna TJ. A simple and cost-effective approach to assessment of pituitary adrenocorticotropin and growth hormone reserve: combined use of the overnight metyrapone test and insulin-like growth factor-I standard deviation scores. J Clin Endocrinol Metab 2008; 93:3763.</a></li><li><a class="nounderline abstract_t">LIDDLE GW, ESTEP HL, KENDALL JW Jr, et al. Clinical application of a new test of pituitary reserve. J Clin Endocrinol Metab 1959; 19:875.</a></li><li><a class="nounderline abstract_t">Steiner H, Bähr V, Exner P, Oelkers PW. Pituitary function tests: comparison of ACTH and 11-deoxy-cortisol responses in the metyrapone test and with the insulin hypoglycemia test. Exp Clin Endocrinol 1994; 102:33.</a></li><li><a class="nounderline abstract_t">Dickstein G, Lahav M, Orr ZS. Single-dose metyrapone test at 06.00 h: an accurate method for assessment of pituitary-adrenal reserve. Acta Endocrinol (Copenh) 1986; 112:28.</a></li><li><a class="nounderline abstract_t">Soule S, Van Zyl Smit C, Parolis G, et al. The low dose ACTH stimulation test is less sensitive than the overnight metyrapone test for the diagnosis of secondary hypoadrenalism. Clin Endocrinol (Oxf) 2000; 53:221.</a></li><li><a class="nounderline abstract_t">Jubiz W, Meikle AW, West CD, Tyler FH. Single-dose metyrapone test. Arch Intern Med 1970; 125:472.</a></li><li><a class="nounderline abstract_t">Staub JJ, Noelpp B, Girard J, et al. The short metyrapone test: comparison of the plasma ACTH response to metyrapone and insulin-induced hypoglycaemia. Clin Endocrinol (Oxf) 1979; 10:595.</a></li><li><a class="nounderline abstract_t">Monaghan PJ, Owen LJ, Trainer PJ, et al. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone. Ann Clin Biochem 2011; 48:441.</a></li><li><a class="nounderline abstract_t">Jubiz W, Matsukura S, Meikle AW, et al. Plasma metyrapone, adrenocorticotropic hormone, cortisol, and deoxycortisol levels. Sequential changes during oral and intravenous metyrapone administration. Arch Intern Med 1970; 125:468.</a></li><li><a class="nounderline abstract_t">Giordano R, Picu A, Bonelli L, et al. Hypothalamus-pituitary-adrenal axis evaluation in patients with hypothalamo-pituitary disorders: comparison of different provocative tests. Clin Endocrinol (Oxf) 2008; 68:935.</a></li><li><a class="nounderline abstract_t">Dolman LI, Nolan G, Jubiz W. Metyrapone test with adrenocorticotrophic levels. Separating primary from secondary adrenal insufficiency. JAMA 1979; 241:1251.</a></li><li><a class="nounderline abstract_t">Schlegel A. Metyrapone stimulation test to diagnose central adrenal insufficiency. Lancet Diabetes Endocrinol 2015; 3:407.</a></li><li><a class="nounderline abstract_t">Suliman AM, Smith TP, Labib M, et al. The low-dose ACTH test does not provide a useful assessment of the hypothalamic-pituitary-adrenal axis in secondary adrenal insufficiency. Clin Endocrinol (Oxf) 2002; 56:533.</a></li><li><a class="nounderline abstract_t">English K, Inder WJ, Weedon Z, et al. Prospective evaluation of a week one overnight metyrapone test with subsequent dynamic assessments of hypothalamic-pituitary-adrenal axis function after pituitary surgery. Clin Endocrinol (Oxf) 2017; 87:312.</a></li><li><a class="nounderline abstract_t">Lamprecht A, Sorbello J, Jang C, et al. Secondary adrenal insufficiency and pituitary dysfunction in oral/transdermal opioid users with non-cancer pain. Eur J Endocrinol 2018; 179:353.</a></li><li><a class="nounderline abstract_t">Obrynba KS, Hoffman RP, Repaske DR, et al. No central adrenal insufficiency found in patients with Prader-Willi syndrome with an overnight metyrapone test. J Pediatr Endocrinol Metab 2018; 31:809.</a></li><li><a class="nounderline abstract_t">Endert E, Ouwehand A, Fliers E, et al. Establishment of reference values for endocrine tests. Part IV: Adrenal insufficiency. Neth J Med 2005; 63:435.</a></li><li><a class="nounderline abstract_t">Spiger M, Jubiz W, Meikle AW, et al. Single-dose metyrapone test: review of a four-year experience. Arch Intern Med 1975; 135:698.</a></li><li><a class="nounderline abstract_t">Nolan GE, Smith JB, Chavre VJ, Jubiz W. Spurious overestimation of plasma cortisol in patients with chronic renal failure. J Clin Endocrinol Metab 1981; 52:1242.</a></li><li><a class="nounderline abstract_t">Feek CM, Bevan JS, Ratcliffe JG, et al. The short metyrapone test: comparison of the plasma ACTH response to metyrapone with the cortisol response to insulin-induced hypoglycaemia in patients with pituitary disease. Clin Endocrinol (Oxf) 1981; 15:75.</a></li><li><a class="nounderline abstract_t">Owen LJ, Halsall DJ, Keevil BG. Cortisol measurement in patients receiving metyrapone therapy. Ann Clin Biochem 2010; 47:573.</a></li><li><a class="nounderline abstract_t">Amlashi FG, Swearingen B, Faje AT, et al. Accuracy of Late-Night Salivary Cortisol in Evaluating Postoperative Remission and Recurrence in Cushing's Disease. J Clin Endocrinol Metab 2015; 100:3770.</a></li><li><a class="nounderline abstract_t">Alexandraki KI, Kaltsas GA, Isidori AM, et al. Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. Eur J Endocrinol 2013; 168:639.</a></li></ol></div><div id="topicVersionRevision">Topic 162 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2547830" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Short loop adrenocorticotropin (ACTH) feedback after ACTH-(1-24) injection in man is an artifact of the immunoradiometric assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22998100" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Comparison of the overnight metyrapone and glucagon stimulation tests in the assessment of secondary hypoadrenalism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9302385" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8013141" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The overnight single-dose metyrapone test is a simple and reliable index of the hypothalamic-pituitary-adrenal axis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12466339" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Combined stimulation of adrenocorticotropin and compound-S by single dose metyrapone test as an outpatient procedure to assess hypothalamic-pituitary-adrenal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18664544" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A simple and cost-effective approach to assessment of pituitary adrenocorticotropin and growth hormone reserve: combined use of the overnight metyrapone test and insulin-like growth factor-I standard deviation scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14416789" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical application of a new test of pituitary reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8005206" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pituitary function tests: comparison of ACTH and 11-deoxy-cortisol responses in the metyrapone test and with the insulin hypoglycemia test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3716755" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Single-dose metyrapone test at 06.00 h: an accurate method for assessment of pituitary-adrenal reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931104" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The low dose ACTH stimulation test is less sensitive than the overnight metyrapone test for the diagnosis of secondary hypoadrenalism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4313728" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Single-dose metyrapone test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/225068" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The short metyrapone test: comparison of the plasma ACTH response to metyrapone and insulin-induced hypoglycaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21813575" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4313727" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Plasma metyrapone, adrenocorticotropic hormone, cortisol, and deoxycortisol levels. Sequential changes during oral and intravenous metyrapone administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18031311" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hypothalamus-pituitary-adrenal axis evaluation in patients with hypothalamo-pituitary disorders: comparison of different provocative tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/216821" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Metyrapone test with adrenocorticotrophic levels. Separating primary from secondary adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26003755" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Metyrapone stimulation test to diagnose central adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11966747" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The low-dose ACTH test does not provide a useful assessment of the hypothalamic-pituitary-adrenal axis in secondary adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28815741" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Prospective evaluation of a week one overnight metyrapone test with subsequent dynamic assessments of hypothalamic-pituitary-adrenal axis function after pituitary surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30324794" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Secondary adrenal insufficiency and pituitary dysfunction in oral/transdermal opioid users with non-cancer pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29959886" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : No central adrenal insufficiency found in patients with Prader-Willi syndrome with an overnight metyrapone test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16397312" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Establishment of reference values for endocrine tests. Part IV: Adrenal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1052666" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Single-dose metyrapone test: review of a four-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7229002" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Spurious overestimation of plasma cortisol in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6273024" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The short metyrapone test: comparison of the plasma ACTH response to metyrapone with the cortisol response to insulin-induced hypoglycaemia in patients with pituitary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926474" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cortisol measurement in patients receiving metyrapone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26196950" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Accuracy of Late-Night Salivary Cortisol in Evaluating Postoperative Remission and Recurrence in Cushing's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23371975" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
